A Summary of Safety of Gadofosveset (MS-325) at 0.03 mmol/kg Body Weight Dose

Shamsi, Kohkan; Yucel, E K; Chamberlin, Paul

doi:10.1097/01.rli.0000242836.25299.8f

Cited by 55 publications

(31 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3). At the recommended dose of 0.03 mmol/kg the safety profile is comparable to that of other gadolinium contrast agents as reported in the literature [32].…”

Section: Gadolinium-based Bpasupporting

confidence: 64%

MR angiography with blood pool contrast agents

2007

View full text Add to dashboard Cite

“…3). At the recommended dose of 0.03 mmol/kg the safety profile is comparable to that of other gadolinium contrast agents as reported in the literature [32].…”

Section: Gadolinium-based Bpasupporting

confidence: 64%

MR angiography with blood pool contrast agents

2007

View full text Add to dashboard Cite

“…Gadofosveset trisodium is a blood pool MRI contrast agent that circulates for 2-3 hr after intravenous injection 15,16 . Its safety profile is similar to those of traditional extravascular extracellular MRI contrast agents 17 . It allows steadystate imaging of the vasculature over a period of 1 hr.…”

Section: Introductionmentioning

confidence: 60%

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Mani

Alie

Ramachandran

et al. 2015

JoVE

View full text Add to dashboard Cite

We evaluated a magnetic resonance venography (MRV) approach with gadofosveset to quantify total thrombus volume changes as the principal criterion for treatment efficacy in a multicenter randomized study comparing edoxaban monotherapy with a heparin/warfarin regimen for acute, symptomatic lower extremities deep vein thrombosis (DVT) treatment. We also used a direct thrombus imaging approach (DTHI, without the use of a contrast agent) to quantify fresh thrombus. We then sought to evaluate the reproducibility of the analysis methodology and applicability of using 3D magnetic resonance venography and direct thrombus imaging for the quantification of DVT in a multicenter trial setting. From 10 randomly selected subjects participating in the edoxaban Thrombus Reduction Imaging Study (eTRIS), total thrombus volume in the entire lower extremity deep venous system was quantified bilaterally. Subjects were imaged using 3D-T1W gradient echo sequences before (direct thrombus imaging, DTHI) and 5 min after injection of 0.03 mmol/kg of gadofosveset trisodium (magnetic resonance venography, MRV). The margins of the DVT on corresponding axial, curved multi-planar reformatted images were manually delineated by two observers to obtain volumetric measurements of the venous thrombi. MRV was used to compute total DVT volume, whereas DTHI was used to compute volume of fresh thrombus. Intra-class correlation (ICC) and Bland Altman analysis were performed to compare inter and intra-observer variability of the analysis. The ICC for inter and intra-observer variability was excellent (0.99 and 0.98, p <0.001, respectively) with no bias on Bland-Altman analysis for MRV images. For DTHI images, the results were slightly lower (ICC = 0.88 and 0.95 respectively, p <0.001), with bias for inter-observer results on Bland-Altman plots. This study showed feasibility of thrombus volume estimation in DVT using MRV with gadofosveset trisodium, with good intra-and inter-observer reproducibility in a multicenter setting. Video LinkThe video component of this article can be found at

show abstract

“…and the gadolinium chelate MS-325 have already completed phase 3 clinical trials. 17,83 In the near future, molecular MRI is therefore likely to become a routine technique in basic science investigation and to streamline the development of novel pharmaceuticals. In the clinical realm, molecular MRI has the potential to facilitate the early detection of cardiovascular disease, refine risk assessment, aid in the selection of individualized thera- 74 Tumor cells that express the receptor have a significant increase in transverse relaxivity (decrease in T2) after systemic injection of a CLIO-streptavidin conjugate.…”

Section: Resultsmentioning

confidence: 99%

Molecular Magnetic Resonance Imaging in Cardiovascular Medicine

2007

View full text Add to dashboard Cite

T he ability of magnetic resonance imaging (MRI) to evaluate cardiovascular pathophysiology at several levels is one of the strengths of the technique. As shown in Figure 1, cardiac phenotype can be assessed at the wholeorgan level by cine MRI, at the regional level with strain, perfusion, and viability imaging, and at the metabolic level with spectroscopic techniques. 1,2 However, MRI of biological processes at the cellular and subcellular level (molecular MRI) has been studied most extensively in other disease states such as cancer. 3,4 Molecular MRI techniques are, however, being increasingly developed for cardiovascular applications and, if fully developed, have the potential to make a significant impact on the practice of cardiovascular medicine.The advantages of an MRI-based approach to molecular imaging reflect the general attributes of the technique. MRI is noninvasive, tomographic, nonionizing, and able to generate images with high spatial resolution and excellent soft tissue contrast. In the initial portion of the present review, the technology that underlies molecular MRI agents is reviewed. The application of these agents to the imaging of myocardial disease, atherosclerosis, and stem cell therapy in the heart is then discussed. Finally, the potential of multispectral and hybrid imaging techniques is explored.

show abstract

A Summary of Safety of Gadofosveset (MS-325) at 0.03 mmol/kg Body Weight Dose

Cited by 55 publications

References 28 publications

MR angiography with blood pool contrast agents

MR angiography with blood pool contrast agents

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Molecular Magnetic Resonance Imaging in Cardiovascular Medicine

Contact Info

Product

Resources

About